| 2016-11-29 07:05:42|
NVLS 07:05 11/29 11/29/16
Nivalis Therapeutics downgraded on lack of drug efficacy at Stifel
As noted earlier, Stifel downgraded Nivalis to Hold from Buy. Analyst Thomas Shrader downgraded the stock after the company's cavosonstat for CF did not show meaningful efficacy in a Phase II trial. Target to $3.25 from $16.